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Purpose:  Usher  syndrome  type  I  (USH1)  is  an  autosomal  recessive  disorder  characterized  by  severe-profound
sensorineural hearing loss, retinitis pigmentosa, and vestibular areflexia. To date, five USH1 genes have been identified.
One of these genes is Usher syndrome 1C (USH1C), which encodes a protein, harmonin, containing PDZ domains. The
aim of the present work was the mutation screening of the USH1C gene in a cohort of 33 Usher syndrome patients, to
identify the genetic cause of the disease and to determine the relative involvement of this gene in USH1 pathogenesis in
the Spanish population.
Methods: Thirty-three patients were screened for mutations in the USH1C gene by direct sequencing. Some had already
been screened for mutations in the other known USH1 genes (myosin VIIA [MYO7A], cadherin-related 23 [CDH23],
protocadherin-related 15 [PCDH15], and Usher syndrome 1G [USH1G]), but no mutation was found.
Results: Two novel mutations were found in the USH1C gene: a non-sense mutation (p.C224X) and a frame-shift mutation
(p.D124TfsX7). These mutations were found in a homozygous state in two unrelated USH1 patients.
Conclusions: In the present study, we detected two novel pathogenic mutations in the USH1C gene. Our results suggest
that mutations in USH1C are responsible for 1.5% of USH1 disease in patients of Spanish origin (considering the total
cohort of 65 Spanish USH1 patients since 2005), indicating that USH1C is a rare form of USH in this population.
Usher  syndrome  (USH;  OMIM  276900-2;  OMIM
276905; OMIM 605472) is an autosomal recessive disorder
characterized  by  sensorineural  hearing  loss,  variable
vestibular dysfunction, and visual impairment due to retinitis
pigmentosa (RP).
Usher  syndrome  is  the  most  common  form  of  deaf-
blindness of genetic origin, representing 50% of cases [1].
This disease shows a prevalence of 3.2–6.2/100,000 people
[2-4].
Three clinical types of USH (types I, II, and III; USH1,
USH2, and USH3) are recognized mainly on the basis of the
severity and progression of hearing loss and the age of onset
of RP [5]. Usher syndrome type I (USH1) is the most severe
form, and it is characterized by congenital profound deafness,
vestibular areflexia, and prepubertal onset of RP. To date,
seven  loci  (USH1B-USH1H)  have  been  mapped  and  five
genes have been identified: myosin VIIA (MYO7A; USH1B),
Usher syndrome 1C (USH1C; USH1C), cadherin-related 23
(CDH23;  USH1D),  protocadherin-related  15  (PCDH15;
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USH1F),  and  Usher  syndrome  1G  (USH1G;  USH1G;
reviewed in Saihan et al. [6]).
The causative gene, USH1C, was identified by positional
cloning [7,8] and encodes a protein, harmonin, containing post
synaptic density protein (Psd-95), Drosophila disc large tumor
suppressor  (DigA)  and  zonula  occludens-1  protein  (ZO1)
(PDZ) domains. This  gene  comprises  28    exons   spanning
approximately  51  kb  of  genomic  DNA.  It  consists  of  20
constitutive exons (exons 1 to 14, 22 to 26, and 28) and eight
alternatively spliced exons (15 to 21 and 27) [9].
USH1C  mutations  are  the  main  cause  of  USH1  in
Acadian and Quebecois patients, due to a mutation founder
effect [10,11]. However, the USH1C gene is only involved in
7% of USH1 cases in the USA and UK populations [12] and
in 6% of the French population [13].
The aim of the present work was mutation screening of
the USH1C gene in our cohort of USH patients, to identify the
genetic cause of the disease and to determine the relative
involvement of this gene in USH1 pathogenesis in the Spanish
population.
METHODS
Subjects: Spanish subjects with Usher syndrome were mainly
recruited from the Federación de Asociaciones de Afectados
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2948de Retinosis Pigmentaria del Estado Español (FAARPEE) and
also from the ophthalmology and ear, nose, throat (ENT)
services of several Spanish hospitals as part of a large study
into the genetics of Usher syndrome in Spain.
This  study  involved  33  unrelated  families  that  were
clinically diagnosed with USH, 23 of which were diagnosed
with USH1 (21 Spanish, one Italian, and one Turkish family)
and ten of which were non-classified (nine Spanish and one
Turkish family). Informed consent was obtained from all these
patients, and this study followed the tenets of the Declaration
of Helsinki.
Subjects were classified as USH1 on the basis of their
clinical  history  and  ophthalmologic,  audiometric,  and
vestibular tests [2].
The MYO7A, CDH23, PCDH15, and USH1G genes were
completely sequenced in 11 of these patients, and 19 were
analyzed by microchip (Asper Biotech, Tartu, Estonia) for the
molecular diagnosis of Usher syndrome. The genetic etiology
of the disease in those individuals could not be determined
from those previous investigations. The other three patients
came to our laboratory at the time USH1C screening was
implemented,  and  they  had  not  undergone  any  previous
screening or chip analysis.
TABLE 1. PRIMERS FOR USH1C GENE.
Exon Primer Sequence (5′-3′) Size (bp)
1 1D-N CGACTCAGCACCTTCGACTC 271
  1R-N TCCGGAGTCCCAGAAGCCTG  
2 2-D GGTGGTCTGCATAGGTCTGA 375
  2-R TCCAGGAGCCGTGAGCATC  
3–4 3–4-D AGTGGTCTACTCCATTCCTAA 625
  3–4-R CCGAAGGCTCAGAAAAGTGG  
5 5-D-N TGCCACCTGAACCTGGGATC 276
  6-R TAGAGCCTCCAGCCAGCCTCCAC  
5–8 5–8-D-N GAGCATCGGTGGTGAGTCTG 1191–1461 (the length of the amplicon
is variable because of the presence of a
VNTR in intron 5)
  5–8-R-N TGAGGAAGGGGAGGGCAATAG  
9 9D GGCTGAAGAGGTAGGCAGTC 376
  9R AGGGTCAAACATCCCCAGTC  
10–12 10–12-D CCACCAGAGCTTTCCAACTG 937
  10–12-R ACAGCGGGCAGGAAGCAAG  
13–14 13–14-D ATAACGTCCCCCAAAACCAA 793
  13–14-R CACCAAGGGCTATCCATCTA  
15 15-D-N ACCTCACAGCTCCCATGGAG 285
  15-R-N CTGAAGCTGGGTGTCTGCAC  
16 16-D TGTTCTGCAACCAAGGCAGG 350
  16-R AACAGGCCAAGTCACACCATT  
17 17-D GGCCTTCCTGTCCTAAACCTG 441
  17-R GCTCACTCCACCCTTGTATGC  
18–19 18–19-D CCTTGAGGGCCAGTTGGAACA 1400
  18–19-R GAGGACATGGGAAACAGCAGT  
20 20-D GCCGCTCAGTAGTTTCTGTG 445
  20-R CTGCATTTTTGTCCCACCTC  
21 21-D-N AGGGACATTGGCACGGCAG 219
  21-R-N GAAGTGGCACAGAGTGGGAG  
22–24 22–24-D CCATTCATCCCCCTACTCC 1092
  22–24-R GTGGTCACCTGTTTGCTTTC  
25 25-D TTTCAGAACCCAGGCTCAG 316
  25-R GGCATCCTATTGTGAGACC  
26 26-D TAGAAACGTCCTCAGACCAT 339
  26-R GCTTGGGCCATTCCTTCAG  
27 27-D GGAGCCCAGTGAAAGGAGAA 295
  27-R GACGCCAGTCCAAAGAACCT  
28 28-D TGCTCTGGCTGGGCTGAGT 628
  28-R ATAGGGGCCACAAACCTTAT  
Exons 2, 3–4, 9, 10–12, 13–14, 16, 17, 18–19, 20, 22–24, 25, 26, 27, and 28 were amplified using primers previously described
by Verpy et al. [8]. For exons 1, 5, 5–8, 15, and 21 new primers were designed.
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2949Mutation  screening:  Genomic  DNA  was  extracted  from
leucocytes  from  peripheral  blood  samples.  All  28  exons,
including intron-exon boundaries of the USH1C gene, were
amplified using primers previously described by Verpy et al.
[8] with some modifications and standard PCR conditions (see
Table 1).Amplification conditions were 95 °C 5 min followed
by 35 cycles of 30 s at 95 °C, 30 s at an annealing temperature
specific for each exon and 30 s at 72 °C.
PCR  products  were  sequenced  using  manufacturer’s
recommendations (Applied Biosystems, Carlsbad, CA). The
sequences  obtained  were  compared  with  the  consensus
sequence NM_153676.2 for exons 1–14 and 16–28, and with
the consensus sequence NM_005709.2 for exon 15, using the
BLAST program.
In  those  cases  where  mutations  were  detected,  we
performed segregation analysis. For the construction of family
trees, we used Cyrillic version 2.02 software (Oxfordshire,
UK).
Computational analysis of splicing variants: To analyze the
effect of variants in the splice prediction and the structure of
donor and acceptor sites, in silico analyses were performed.
Three  programs  were  used:  Spliceview  (The  National
Research  Council,  Institute  for  Biomedical  Technologies,
Milan, Italy), NNSPLICE 0.9 from the Berkeley Drosophila
Genome Project, and Human Splicing Finder, Version 2.4
(French Institute of Health and Medical Research, Inserm
U827, Montpellier, France).
Computational analysis of missense variants: The predicted
effect  of  each  missense  variant  was  studied  using  three
different analysis programs: Sort Intolerant From Tolerant
(SIFT;  J.  Craig  Venter  Institute,  San  Diego,  CA),  which
predicts whether a change is innocuous or deleterious; Pmut
(Institut  de  Recerca  Biomedica,  Barcelona,  Spain),  which
predicts if an amino acid change is neutral or pathologic; and
PolyPhen  (the  polymorphism  phenotyping  program;  Bork
Group,  Heidelberg,  Germany),  which  estimates  the
consequence of an amino acid substitution as being possibly
deleterious or deleterious.
RESULTS
Mutation  analysis:  Mutation  screening  was  performed  on
members  of  33  USH  families.  As  a  result,  two  clearly
pathogenic, novel mutations were identified in the USH1C
gene.
The  first  novel  mutation  identified  was  a  non-sense
mutation in exon 8, p.C224X (c.672C>A). This mutation was
found  in  a  homozygous  state  in  a  Spanish  USH1  patient
(family  FRP-233;  patient  RP-1232).  Segregation  analysis
Figure  1.  Segregation  analysis  of  the
mutation  c.672C>A  (p.C224X)
identified  in  family  FRP-233.  A:
Electropherogram corresponding to the
wild  type  sequence  (c.672C).  B:
Electropherogram corresponding to the
healthy mother, carrying the mutation in
heterozygous  state  (c.672C>A).  C:
Electropherogram corresponding to the
patient,  carrying  the  mutation  in
homozygous  state  (c.672A).   Blue
arrow indicates position c.672 is in A,
B and C, D: Family tree showing the
segregation of the p.C224X mutation.
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2950showed that the patient’s healthy mother carried the mutation
in a heterozygous state (Figure 1).
The second novel mutation was a frame-shift mutation,
p.D124TfsX7 (c.369delA). This mutation was identified in an
Italian USH1 patient (family FRP-249; patient RP-1265) in
exon 4 in a homozygous state. Segregation analysis confirmed
that this mutation co-segregates with the disease, and this
deletion was detected in the patient’s healthy parents in a
heterozygous state (Figure 2).
USH1C gene mutation screening allowed us to detect 47
additional sequence variants, 25 of which had previously been
reported as presumably non-pathogenic (see Table 2).
Two novel missense variants, p.S190L and p.G379D,
were identified in our cohort with a low allele frequency. We
performed computational analysis with the programs SIFT,
PolyPhen, and Pmut to infer the pathologic effect of these
variants. These programs generated contradictory results. The
SIFT program predicted that the substitution of a serine for a
lysine in codon 190 (p.S190L) of the protein would affect its
function (score of 0.02; normalized probabilities less than
0.05 are predicted to be deleterious; those greater than or equal
to 0.05 are predicted to be tolerated), but that the change from
glycine to aspartic acid in codon 379 (p.G379D) would not
alter protein function (score of 0.43). Conversely, the program
Pmut predicted that change p.S190L would not alter protein
function, but that change p.G379D was pathologic. Finally,
the  program  PolyPhen  predicted  that  both  substitutions
possibly affected protein function.
An intronic variant, c.1086–12G>A, was identified in a
homozygous state in three affected patients of one Turkish
family (FRP-284; patients RP-1367, RP-1368, and RP-1371).
This family was described as clinically compatible with USH2
by  Simsek  et  al.  [14].  However,  we  performed  a  linkage
analysis for all known loci so far implicated in the Usher
syndrome (data not shown), and we were able to discard
linkage to all of them except for USH1B and USH1C (Figure
3). The haplotype analysis of the USH1B locus was limited
because  it  was  based  only  on  one  informative  marker.
However,  the  involvement  of  this  locus  was  reduced  by
mutation  screening  of  the  MYO7A  gene  [15].  Thus,  we
included this family in the USH1C mutation screening. The
analyses of predictions of the effects of the variant c.1086–
12G>A  indicated  that  the  acceptor  site  would  not  be
recognized (Spliceview) and that the score for acceptor site
recognition would be reduced slightly from 48 to 45 and from
83.79 to 83.6 for NNSPLICE and Human Splicing Finder,
respectively. In addition, we looked for this change at the
NCBI  dbSNP.  This  variant  (rs11024318)  has  an  allele
frequency  of  G  (98.3%)  and  A  (1.7%)  in  the  European
population (HapMap-Ceu/ss52068547), and it is present in a
homozygous state in 8.7% of an African-American population
(AFD_EUR_PANEL/ss23639768)  and  in  6.1%  of  a  sub-
Saharan African population (HapMap-YRI/ss52068547).
In the present work, we performed a mutation screening
of the USH1C gene by direct sequencing in 33 USH patients.
Thirty of the individuals were of Spanish origin; 21 of them
were  clinically  USH1,  but  we  could  not  obtain  sufficient
clinical data to classify the remaining nine individuals. As a
result, we only detected two clearly pathogenic mutations in
two  USH1  families  of  Italian  and  Spanish  origins.  These
results indicate that mutations in USH1C are responsible for
1.5% of incidences of USH1 in patients of Spanish origin
(considering the total cohort of 65 Spanish USH1 patients that
have  been  studied  since  2005  for  the  five  USH1  genes
[16-19]). This would suggest that USH1C is a rare form of
USH in this population.
Figure  2.  Segregation  analysis  of  the
mutation  c.369delA  (p.D124TfsX7)
identified  in  family  FRP-249.  A:
Electropherogram corresponding to the
wild  type  sequence   (blue    arrow
indicating c.369A nucleotide position).
B: Electropherogram corresponding to
the  patient,  carrying  the  mutation  in
homozygous  state  (c.369delA).  C:
Family tree showing the segregation of
the p.D124TfsX7 mutation.
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2951DISCUSSION
To date, few mutation screenings for the USH1C gene have
been performed. Among them, only the studies performed by
Ouyang et al. [12] and Roux et al. [13] were formal molecular
epidemiological studies. These authors reported the USH1C
gene as responsible for the disease in 7% of cases in a cohort
of UK and USA patients, and in 6% of the French USH1
population, respectively.
Eleven clearly pathogenic mutations have so far been
described  in  the  USH1C  gene  [20].  These  mutations  are
distributed along the entire gene, without the existence of hot
spots.
In the present work, the two novel mutations, p.C224X
and p.D124TfsX7, were identified in a homozygous state-the
former in a Spanish family and the latter in an Italian family.
Both families were diagnosed as USH1, and both possessed a
possible consanguineous background, since the parents of the
patients came from small villages in Spain and Sardinia.
Two novel missense variants, p.S190L and p.G379D,
were found in a heterozygous state. The p.S190L variant was
found in the same patient (RP-1232) that possessed mutation
p.C224X in a homozygous state, although in this patient,
mutation p.C224X alone was sufficient to cause the disease.
The p.G379D variant was identified in three affected members
of  the  same  Turkish  family  (RP-1367,  RP-1368,  and
RP-1371),  where  we  also  found  the  nucleotide  change  c.
1086–12G>A (Figure 3B). The nucleotide change c.1086–
12G>A is predicted to abolish a splicing site, based on results
from the in silico analysis program, Spliceview. However, we
found this change as an SNP (rs11024318) in the NCBI SNP
database. Thus, the predicted splicing effect is not evidence
for a pathologic effect of this variant.
The results of this study show that the USH1C gene has
a very low mutation prevalence compared with other USH1
genes. In the total cohort of 65 Spanish USH1 patients, the
MYO7A gene is involved in 35.4% of cases, CDH23 in 15.4%,
PCDH15 in 10.8%, and USH3A in 3%. No mutations have
been described from USH1G ( [15-19] and data not shown).
The USH1C gene mutations represent 1.5% of cases.
Thus, 33.8% of our USH1 patients remain genetically
uncharacterized. We cannot exclude (1) the possibility of the
presence of large rearrangements undetectable by PCR, as has
been reported for the PCDH15 gene [21,22] (2) the presence
of mutations responsible for clinical type I in USH2 genes (3)
the  presence  of  mutations  located  in  promoter  regions  or
introns far from the consensus sequences of splicing and (4)
TABLE 2. NOVEL DNA SEQUENCE VARIANTS IN THE USH1C GENE IDENTIFIED FROM OUR COHORT OF 33USH PATIENTS.
Exonic variants
Exon Nucleotide change Amino acid
change
SNPs                         Allele frequency
7 c.569C>T p.S190L   1/66
14 c.1136G>A p.G379D   1/66
Intronic variants  
Intron Nucleotide change   SNPs Allele frequency
2 c.104+23T>C     5/66
  c.105–54T>G     4/66
5 c.496+33A>G   rs12795083 8/66
  c.496+66G>T   rs45552041 5/66
  c.497–104A>G     6/66
  c.497–72G>T   rs28671305 4/66
7 c.580–51T>C   rs36001077 4/66
9 c.760–66T>C   rs4757539 19/66
10 c.819+10G>C   rs41282936 1/66
  c.819+66A>G     3/66
13 c.1086–12G>A   rs11024318 2/66
25 c.2490+56G>C     1/66
  c.2491–100C>G     1/66
26 c.2547–21T>C     1/66
  c.2547–11T>C   rs10832795 26/66
27 c.2656–47C>T   rs2072225 9/66
28 c.3141+215A>G     25/66
  c.3141+190C>T     25/66
  c.3141+49T>C     24/66
  c.*420_423delAACA 3′UTR     2/66
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2952mutations associated with USH1 in still unknown genes in
these unsolved cases. The genes coding for proteins involved
in  the  “Usher  protein  network”  and  other  genes  with
expression profiles in the retina and inner ear are excellent
candidates. Consequently, mutation screening of these genes
will facilitate determination as to whether some are implicated
in the disease.
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